2. Academic Validation
  3. Review of cariprazine in management of psychiatric illness

Review of cariprazine in management of psychiatric illness

  • Ment Health Clin. 2018 Mar 23;7(5):221-229. doi: 10.9740/mhc.2017.09.221.
Rebecca H Campbell 1,  Michael Diduch 1,  Kristen N Gardner 2,  Christopher Thomas 3
Affiliations

Affiliations

  • 1 PGY2 General Pharmacy Practice Resident, Chillicothe VA Medical Center, Chillicothe, Ohio.
  • 2 (Corresponding author) Clinical Pharmacy Specialist - Behavioral Health, Kaiser Permanente Colorado, Highline Behavioral Health Clinic, Denver, Colorado, [email protected].
  • 3 Director, PGY-1 and PGY-2 Residency Programs, Clinical Pharmacy Specialist in Psychiatry, Chillicothe VA Medical Center, Chillicothe, Ohio, and Clinical Associate Professor of Pharmacology, Heritage College of Osteopathic Medicine, Athens, Ohio.
PMID: 29955527 DOI: 10.9740/mhc.2017.09.221
Abstract

Schizophrenia and bipolar disorder are severe and debilitating psychiatric disorders. Despite the availability of numerous antipsychotic drugs, many patients still experience poor outcomes and treatment-limiting adverse side effects. Cariprazine is a novel antipsychotic with unique pharmacodynamic and pharmacokinetic properties. It is both a dopamine type 2 and dopamine type 3 partial agonist with 2 equipotent metabolites, desmethyl cariprazine and didesmethyl cariprazine, of which didesmethyl cariprazine has a half-life of 1 to 3 weeks. The objective of this article is to review the literature regarding efficacy and tolerability of cariprazine in the management of psychiatric disorders to determine its current place in therapy.

Keywords

bipolar disorder; partial dopamine agonist; pharmacotherapy; schizophrenia.

Figures
Products